The relationship between hemorrhage and low platelet count was first established in patients with acute leukemia, and has been widely applied to thrombocytopenic patients, including BMT patients. Yet, the role of thrombocytopenia in bleeding post BMT has not been systematically studied. We evaluated the risk of bleeding and outcome associated with thrombocytopenia in BMT patients who had prophylactic platelet transfusions at a trigger of 20 × 10 9 /l. Thrombocytopenia was investigated in 321 patients with moderate or severe bleeding (BLD), and in a matched comparison group of 287 patients who did not bleed (NBLD). Profound thrombocytopenia (р10 × 10 9 /l) was found in 8.6% of the BLD patients during the week before the bleeding onset, significantly more frequent than in NBLD patients (2.1% to 4%, P Ͻ 0.02), during weeks 2 to 6 post BMT (the period when 75% of the bleeding initiated). On the first day of bleeding, platelet counts Յ10 × 10 9 /l were found in 13.5%, 11-20 × 10 9 /l in 20.4%, and Ͼ20 × 10 9 /l in 66.1% of all episodes. Overall survival in BLD patients was not associated with the severity of thrombocytopenia before bleeding onset. Severity of thrombocytopenia was significantly associated with reduced survival in NBLD patients. We concluded that bleeding post BMT was significantly associated with thrombocytopenia, but the attributable risk of bleeding from profound thrombocytopenia was not large. Thrombocytopenia may be an important clinical sign in NBLD patients, and should be further explored in relation to acute toxicities other than bleeding. Bone Marrow Transplantation (2001) 27, 65-72.
/l. [2] [3] [4] Platelet transfusion therapy has greatly reduced the risk of life-threatening hemorrhage in patients with acute leukemia. 4, 5 However, serious concerns relate to the risks of transmitted infections as well as the high costs of multiple platelet transfusions.
The appropriate trigger for prophylactic transfusions has been the subject of controversy. [6] [7] [8] [9] [10] [11] [12] [13] The difficulty in setting a rational policy for prophylactic transfusions resulted from the scant number of properly controlled trials assessing the risk of thrombocytopenic bleeding, and uncertainties of the role of other risk factors for bleeding. 2 Recent studies have examined the incidence of bleeding and outcome with triggers of 10 × 10 9 /l and 20 × 10 9 /l. [14] [15] [16] [17] When patients were stratified for conditions associated with increased bleeding (eg fever, infections, coagulation disorders), these studies reported similar bleeding incidence with the lower and higher triggers. The results of these reports may assist in developing methods to predict when thrombocytopenic patients are at substantial risk for bleeding.
Gil-Fernandez et al 18 investigated 190 BMT patients for bleeding complications with triggers of 10 × 10 9 /l and 20 × 10 9 /l. In 24 patients who bled they identified 'high platelet consumption factors' (eg disseminated intravascular coagulation, fever, sepsis, veno-occlusive disease of the liver, mucositis) as associated risk factors for bleeding. Thrombocytopenia was significantly associated with intracranial hemorrhage after BMT, 19, 20 but many reports on bleeding from other sites (gastrointestinal hemorrhage, hemorrhagic cystitis, pulmonary hemorrhage) have not identified thrombocytopenia as a main cause of bleeding, implicating other etiologies (eg preparative regimen toxicity, infections, graft-vs-host disease). [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] We have previously studied 1402 patients for bleeding complications within 100 days after BMT. 33 Bleeding was found to be a common complication, which was significantly associated with reduced survival. The goals of the present work were to examine the role of thrombocytopenia in bleeding in a large cohort of BMT patients who were treated prophylactically to keep their platelet counts Ͼ20 × 10 9 /l, and to examine the outcome associated with severe thrombocytopenia in bleeding (BLD) and non-bleeding (NBLD) patients.
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Patients and methods
Patients group
A total of 1402 patients underwent BMT at the Johns Hopkins Hospital for hematologic diseases or solid tumors from 1 January 1986 to 30 June 1995. All 1402 patients were evaluated for bleeding complications. 33 The role of thrombocytopenia in the pathogenesis of bleeding was investigated in 321 BLD patients with moderate or severe bleeding episodes, and in 287 case control NBLD patients, matched to the BLD patients on diagnosis, stage of disease, BMT type, preparative regimen and age (pediatric or adult age groups). Comparative information on 321 BLD and 287 NBLD patients is given in Table 1 . 'Others' in the section of diagnoses were mainly solid tumors in pediatric patients. Categorization of diseases to good and poor risk prognosis has been previously published. 33 Four transplants grouped as 'others' included two peripheral blood stem cell transfusion, one syngeneic transplant and one cord blood transplant. The protocols of preparative regimens used have been previously published. 33 
Evaluation of bleeding
A daily score of bleeding intensity was prospectively assigned to every hospitalized BMT patient by the blood a In parenthesis are given the numbers of good and poor risk prognosis patients, for each diagnosis. BLD = patients who bled within 100 days post BMT; NBLD = patients who did not bleed; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; HD = Hodgkin's disease; NHL = non-Hodgkin's lymphomas; MM = multiple myeloma; AA = aplastic anemia; Bu = Busulfan; Cy = cyclophosphamide; TBI = total body irradiation; VP = etoposide; CsA = cyclosporin A; Thio = Thiotepa. transfusion service. The scoring integrates clinical assessment, daily hematologic laboratory values, and daily red blood cell (RBC) usage. The classification of bleeding has been previously described. 33 In brief, score 0 signified no bleeding. Score 1 was given for occult blood in body secretions (including mild petechia or minimal vaginal spotting). Score 2 was assigned for minor bleeding which did not require RBC transfusion over the routine transfusion needs (eg ecchymosis, epistaxis, line oozing, vaginal bleeding, skin bleeding, mild hematemesis, melena, mild hematuria). Hemorrhage causing rapid falls in hematocrit, necessitating one or more units of RBC transfusions per day over the expected rate of an individual, or failure to obtain a post-transfusion increment while actively bleeding, resulted in a score 3. Life threatening hemorrhage, defined as either massive bleeding causing severe hemodynamic compromise or bleeding into a vital organ (eg intracranial hemorrhage, pericardial hemorrhage, diffuse alveolar hemorrhage), resulted in score 4. Daily scoring of bleeding has been used in the same format along the study period. Reports of daily bleeding scores were reviewed in 1402 patients for primary identification of bleeding within 100 days post BMT.
Based on the daily scores, bleeding was categorized into minor, moderate and severe episodes. Moderate bleeding was defined as more than a week of daily score 2, or 1-2 days of score 3 (within 7 days). Severe bleeding included score 3 for 3 or more days (within 7 days), or any score 4. Minor bleeding (less than a week of daily score 2) was not included in this study.
The first day of the first moderate or severe bleeding episode was determined as the onset of bleeding. Thus, each patient has one record of bleeding onset.
Platelet and blood transfusions
Prophylactic platelet transfusions were given when the morning count was р20 × 10 9 /l. Patients with daily score 2 were usually transfused to keep their platelets Ͼ30 × 10 9 /l. In cases of active bleeding (score 3) the threshold was usually set at 50 × 10 9 /l or higher in life-threatening hemorrhage (score 4). During 1986-1988, 60% of platelet transfusions were apheresis products, the use of which increased yearly. By 1995, 96% of the platelet transfusions were single donor apheresis products. Platelet products were not routinely leukoreduced. Patients who had repeated febrile transfusion reactions that were not controlled with premedications, received products that were filtered at the bedside with a leukoreducing filter. This would have applied to about 1% of the products infused during the 1986-1995 time period. All allogeneic patients were screened for CMV status. Allogeneic patients who tested CMV Ab negative were given products that were transfused from CMV Ab negative donors. Autologous patients were not routinely tested for CMV status until March 1995. Since then, CMV Ab negative autologous patients received CMV Ab negative products, when available. If CMV Ab negative products were not available, these patients received leukoreduced products.
Packed RBC were transfused prophylactically to maintain a hematocrit equal to or above 0.25 volume fraction.
Patients with active bleeding had RBC transfusions as needed, based on the intensity of bleeding and the hemodynamic status.
Evaluation of thrombocytopenia
Platelet counts were measured with an automated counter (Beckman Coulter model STKR; Beckman Coulter Inc, Fullerton, CA, USA). Routinely, platelet counts below 20 × 10 9 /l were verified visually by examining a peripheral smear. When a discrepancy of greater than 10% was observed, phase platelet counts were performed. A morning count was taken daily from every hospitalized BMT patient. Patients had more than one platelet count per day based on clinical indications. All the analyses of this report are based on the lowest count of the day when available, and the morning counts for other days. (In 2326 out of all 5899 days with bleeding there was more than one platelet count recorded per day).
Thrombocytopenia in BLD patients was evaluated during the week before the bleeding onset, and on the first day of bleeding. The analyses included spontaneous bleeding from any source. The severity of thrombocytopenia during the week before bleeding onset was presented by the number of days with low counts (eg 0/7, 1/7, . . . 7/7), grouped as 0-2 vs 3-7 days. In cases where the patient had less than seven records, the tested period was extended up to 10 days, to include seven records of platelet counts before bleeding onset.
In the case control NBLD patients, as there was no bleeding event, we focused on weeks 2, 3, 4, 5, and 6 post BMT, the period when 75% of the bleeding episodes initiated. Thrombocytopenia was assessed weekly, in the same manner as in the BLD group, except that we did not extend the 7 day period in NBLD. Thus, a patient with less than six daily platelet counts per week was excluded from that week analysis. The total number of NBLD patients evaluable was reduced with each subsequent week (due to lack of adequate platelet count data) and included 287, 273, 248, 170 and 114 patients, in weeks 2-6, respectively. However, as 92.5% of the NBLD patients survived the first 50 days post BMT, we assume that reduction in the frequency of blood draws per week was associated with high platelet counts (Ͼ20 × 10 9 /l) rather than with lower counts, and therefore we should not underestimate severe thrombocytopenia in the NBLD population.
Survival estimates
Data on overall survival were available in 303 BLD and 278 case control NBLD patients, for outcome endpoints of death or follow-up ending in December 1995. KaplanMeier estimates of survival 34 were computed from the time of BMT, where marrow infusion was considered day 0. Survival curves were compared using the log-rank test. 35 
Statistical methods
The proportion of patients with low platelet counts (comparing BLD and NBLD patients) were computed by chi-square test. The unadjusted relative risk for bleeding Bone Marrow Transplantation was estimated for those with more days of low platelet counts compared to those with fewer days. 36 Distribution of the severity of thrombocytopenia (before bleeding onset) by the bleeding intensity at the first bleeding day was computed by chi-square test.
Results
Characteristics of the bleeding episodes
The onset of bleeding within 100 days from marrow infusion is shown in Figure 1 . Twenty-five percent of the bleeding had started by day 12, 50% by day 22, and 75% by day 42.
Sixty-one percent of all bleeding episodes (196/321) had one bleeding site, 31.2% (100/321) had two or more bleeding sites, 3.1% (10/321) could not be categorized for number of sites, and in 4.7% (15/321) bleeding sites were not identified.
Gastrointestinal hemorrhage was found in 62% (199/321) of all bleeding episodes, hemorrhagic cystitis in 27.7% (89/321), intracranial hemorrhage in 9% (29/321), and pulmonary hemorrhage in 9.3% (30/321). Other sites (eg epistaxis, vaginal, skin, cardiac, abdominal) accounted for 13.4% (43/321).
Duration of bleeding was less than a week in 24.6% of the patients, 8-14 days in 28.7%, 15-28 days in 27.8%, 29-60 days in 15.6%, and Ͼ60 days in 3.4% of the patients. Table 2 gives an estimate on the proportion of patients with low platelet counts. Table 2a column A, shows the proportion of BLD patients with 0-2 or 3-7 days with platelet counts р20 × 10 9 /l during the week before bleeding onset. Table 2b column A, shows the proportion of BLD patients with 0-2 or 3-7 days with platelet counts р10 × 10 9 /l during the week before bleeding onset. About one third of the Days from marrow infusion Figure 1 The onset of bleeding within 100 days from marrow infusion. Twenty-five percent of bleeding had started by day 12, 50% by day 22, and 75% by day 42, defining weeks 2-6 post BMT to be the period of 'high risk for bleeding'. The proportion of BLD patients with 0-2 or 3-7 days of platelet counts р20 × 10 9 /l during the week before bleeding onset is given in Table 2a column A. The proportion of BLD patients with 0-2 or 3-7 days of platelet counts р10 × 10 9 /l during the week before bleeding onset is given in Table 2b column A. Corresponding values in NBLD patients are given weekly, for weeks 2-6 post BMT in columns B-F, Table 2a and b. a Column percentage. P value compares the results in BLD patients with each week in NBLD patients, showing that low platelet counts were significantly more frequent in BLD patients. The relative risk for bleeding in a patient with 3-7 days of platelet counts р10 × 10 9 /l was 1.2-1.6 higher than the risk in a patient with 0-2 days of platelet counts р10 × 10 9 /l (Table 2b) .
Thrombocytopenia in BLD and NBLD patients
bleeders had platelet counts lower than the prophylactic goal for a significant time (3-7 days) before bleeding onset. Yet, profound thrombocytopenia (3-7 days with platelet counts р10 × 10 9 /l) was found in only 8.6% of all bleeders. The proportion of NBLD patients with low platelet counts during weeks 2-6 post BMT (the period when 75% of bleeding initiated) is given in Table 2a , columns B-F (for values р20 × 10 9 /l), and in Table 2b , columns B-F (for values р10 × 10 9 /l). The percent of NBLD patients with low platelet counts was significantly lower in each week (2-6 post BMT) as compared with BLD patients (the week before bleeding onset).
The relative risk for bleeding in a patient with 3-7 days of platelet counts р10 × 10 9 /l was 1.2-1.6 higher than the risk for bleeding in a patient with 0-2 days of platelet counts р10 × 10 9 /l (Table 2b) . These results significantly associate bleeding post BMT with severe thrombocytopenia.
Platelet counts on the first day of bleeding
The distribution of platelet counts on the first bleeding day as analyzed for each bleeding intensity (scores 2, 3 and 4) and for all scores grouped together is shown in Table 3 . Three patients were excluded from this analysis: in two cases bleeding on the first day was secondary to procedure, and in one case the onset of chronic subdural hematoma was uncertain. As can be seen, most of the bleeding episodes initiated with platelet counts Ͼ20 × 10 9 /l. Platelet counts р10 × 10 9 /l were evident in 13.5% of all bleeding events.
The distribution of platelet counts (0-10 × 10 9 /l, 11-20 × 10 9 /l, 21-50 × 10 9 /l and Ͼ50 × 10 9 /l) in score 2 bleeding was similar to the distribution of platelet counts in scores 3 and 4 (grouped together, P = 0.82).
The distribution of platelet counts by sites on the first day of bleeding is given in Table 4 . Significant difference was found in the distribution of platelet counts among gastrointestinal hemorrhage, hemorrhagic cystitis, intracranial hemorrhage and pulmonary hemorrhage (P = 0.003, Kruskal-Wallis test). This difference was due to the distribution in pulmonary hemorrhage. The distributions in gastrointestinal hemorrhage, hemorrhagic cystitis, and intracranial hemorrhage were similar (P = 0.15, Kruskal-Wallis test).
Platelet counts during the active bleeding episodes
Three hundred and twenty-one patients with moderate or severe bleeding had 5899 days of spontaneous bleeding. The distribution of platelet counts in 5581 days with active bleeding (excluding the first day of bleeding) is given in Table 5 . The platelet counts were successfully maintained Ͼ30 × 10 9 /l in 70.6% of the bleeding days. Platelet counts р10 × 10 9 /l were found in only 5.5% of the days with bleeding. Figure 2 shows the distribution of platelet counts on the first bleeding day, and in all other days with bleeding, excluding the first day (relating to Tables 3 and 5 ). In response to therapeutic platelet transfusions, the proportion of days with low platelet counts significantly decreased (P Ͻ 0.0001).
Transfusions
The median number of platelet transfusions per patient within 100 days post BMT was 17 (quartiles 25% and 75% -8 and 32 transfusions), when including all 608 patients. Data on the median number of platelet and RBC transfusions per patient in BLD and NBLD are summarized in Table 6 . Patients who bled used about four times more platelet transfusions as compared with NBLD patients, within the first 100 days after BMT. The distribution of platelet counts on the first bleeding day is given for each bleeding intensity (scores 2, 3 and 4) and for all scores accumulated, in the total of 318 episodes analyzed.
a Raw percentage. The analysis is based on the lowest count of the day. About two thirds of bleeding (65.4%) started with platelet counts Ͼ20 × 10 9 /l (see all scores accumulated). Platelet counts р10 × 10 9 /l were found in 13.5% of all bleeding events. 
Overall survival in BLD and NBLD patients by severity of thrombocytopenia
The median survival of 303 BLD patients was 3.9 months. Median survival of 278 matched control NBLD patients was 21 months (p Ͻ 0.0001). Within 100 days after BMT, 42.4% of the BLD and 12.5% of the NBLD patients died.
In the BLD group, differences in overall survival could not be detected by degree of thrombocytopenia during the week before the bleeding episode ( Figure 3 ): BLD patients Table 5 Platelet counts in 5581 days with active bleeding The platelet counts in 5581 days of active bleeding (excluding the first day of bleeding episode) are given for each bleeding intensity (scores 2, 3 and 4), and for all scores accumulated. /l (n = 124) had a median of 3.4 months. Patients whose lowest platelet counts were equal to or fell below 10 × 10 9 /l (n = 86) had a median survival of 3.6 months (P = 0.53, comparing the three groups).
Distribution of platelet counts Total
In contrast to the BLD group, severity of thrombocytopenia was significantly associated with overall survival in the matched control NBLD patients (Figure 4) . Patients with platelet counts always Ͼ20 × 10 9 /l (group A, n = 54) had a median survival Ͼ50 months, patients with lowest platelet counts between 11 and 20 × 10 9 /l but never р10 × 10 9 /l (group B, n = 144) had a median of 28.2 months, and patients with lowest platelet counts р10 × 10 9 /l (group C, n = 80) had a median survival of 10.8 months (P = 0.0386 comparing groups A and B, P = 0.0022 comparing groups B and C). The survival of group C NBLD was similar to survival of 143 patients with moderate bleeding (7.1 months, P = 0.3), but statistically better than survival of 144 patients with severe bleeding (3.0 months, P Ͻ 0.0001).
Discussion
Acute bleeding after BMT was significantly associated with thrombocytopenia but the attributable risk of bleeding from profound thrombocytopenia was not large. Daily platelet count (×109/l) Figure 2 The distribution of platelet counts on the first bleeding day (318 days, in white) and in all the following days with active bleeding (5581 days, in black). With therapeutic platelet transfusions, the proportion of days that associated with low platelet counts (р10 × 10 9 l) decreased from 13.5% to 5.5% (P Ͻ 0.0001).
Table 6
Platelet and red blood cell transfusions within the first 50 and 100 days from marrow infusion The median number and quartiles 25% and 75%, in parenthesis, of platelet and red blood cell (RBC) transfusions per patient, in the first 50 and 100 days post BMT. Patients who bled (BLD) consumed about four times more platelet and RBC transfusions as compared with patients who did not bleed (NBLD) within 100 days after BMT.
bocytopenia was evident in only the minority of bleeding post BMT. Overall survival of BLD patients did not relate to the severity of thrombocytopenia before bleeding onset. However, reduced survival was significantly associated with severity of thrombocytopenia in NBLD patients. The majority of patients, both BLD and NBLD, successfully maintained platelet counts Ͼ20 × 10 9 /l with prophylactic platelet transfusions. The overall rate of success in achieving the prophylactic goal was 77%.
Very low platelet counts were significantly associated with bleeding post BMT. The risk of bleeding in a patient with 3-7 (out of 7) days of platelet counts р10 × 10 9 /l was 40-60% higher compared to a patient with 0-2 days with low platelet counts (considering weeks 2-4 post BMT, that sample over 200 NBLD patients). However, the proportion of BLD patients, who had such profound thrombocytopenia prior to the bleeding episode was 8.6% only. In most cases, for most bleeding sites, bleeding episodes started with platelet counts Ͼ20 × 10 9 /l (Tables 3 and 4) . Analysis of the platelet counts by site on the first bleeding day (Table 4) showed that pulmonary hemorrhage was more associated with low platelet counts as compared with bleeding from other sites. Other reports associated intracranial hemorrhage with thrombocytopenia. 19, 20 It is possible that rare, but serious complications are more common with low platelet counts. In our study, samples of both pulmonary and intracranial hemorrhage (on the first bleeding day) were small. The risk of these bleeding from thrombocytopenia should be examined in larger cohorts.
With therapeutic transfusions, the proportion of bleeding days that were associated with platelet counts р10 × 10 9 /l decreased to 5.5% (Figure 2 ). Most days of bleeding were recorded with platelet counts Ͼ30 × 10 gests a role for other factors in the pathophysiology of bleeding after BMT.
Gaydos et al 1 focused attention on the association of bleeding with low platelet counts in leukemic patients. Other studies in non-BMT patients, avoiding the use of aspirin, reported a similar relationship. 11, 17, 37 Recent studies did not specify platelet counts at the time of bleeding onset, although they reported a similar incidence of bleeding with prophylactic triggers of 10 × 10 9 /l and 20 × 10 9 /l. 14, 16 Interestingly, Wandt et al 15 found that serious bleeding was generally not related to low platelet counts in newly diagnosed leukemia patients. However, the number of significant bleeding events in this report was small (n = 7).
In BMT patients, Gil-Fernandez et al 18 reported that only the minority of bleeding (four of 13 bleeding episodes in the 10 × 10 9 /l trigger, and three of 14 bleeding episodes in the 20 × 10 9 /l trigger) started with platelet counts Ͻ10 × 10 9 /l. Our report, showing a higher risk of bleeding with platelet counts р10 × 10 9 /l is in agreement with previous studies. However, a major finding of this study is that most bleeding episodes after BMT started with platelet counts at all values between Ͼ30 ϫ 10 9 /l and 100 ϫ 10 9 /l. It is possible that high-dose therapy with severe acute toxicities may induce bleeding at higher levels of platelet count in BMT patients, as compared with non-BMT patients. The etiology of bleeding in BMT could involve different mechanisms as compared with bleeding in non-BMT patients (eg GVHD after allogeneic transplantation 32 ). Thus, evaluation of bleeding and decisions on preventive therapy in BMT patients should take into consideration factors that may not exist in thrombocytopenic non-BMT patients.
Whereas bleeding is more likely to occur when the platelet counts drop to low levels, presence of other factors may increase the risk of bleeding. Anatomic defects, coagulation disorders, certain medications, the type of leukemia, patient age, fever, and infection, have been associated with bleeding in leukemia patients. 1, 12, [37] [38] [39] In BMT patients, most bleeding has been associated with additional complications (eg fever, VOD 18 ). Considerations of the wide range of conditions that are associated with bleeding was beyond the capacity of this work. Such evaluation could be better addressed in a prospective study. Further investigation is needed to clarify the underlying mechanisms which trigger or aggravate bleeding, eg platelet function in the light of organ dysfunction or vascular damage. Vascular damage has been reported to occur with several acute toxicities after BMT, [40] [41] [42] yet the vasculature remains the most poorly understood with respect to disorders of hemostasis. 43 Identification of underlying mechanisms may greatly assist in predicting the risk of bleeding in thrombocytopenic patients.
Our results show that overall survival of BLD patients was not associated with the severity of thrombocytopenia before onset of bleeding. A major finding of this study is the severely reduced survival of thrombocytopenic NBLD patients, which significantly correlates with the degree of thrombocytopenia. Association of thrombocytopenia with reduced survival has been previously reported in patients with chronic GVHD. [44] [45] [46] The association of thrombocytopenia with reduced survival in NBLD patients may possibly
Bone Marrow Transplantation reflect an association of thrombocytopenia with various acute complications (eg GVHD, infections, VOD), which correlate with reduced survival. Reduction in circulating platelets may be secondary to repair mechanisms of injured endothelium, which has been reported in association with acute toxicities post BMT. [40] [41] [42] Further investigation is needed to evaluate thrombocytopenia as a surrogate clinical marker of acute toxicities (other than bleeding) post BMT.
Prophylactic transfusions with a goal of 20 × 10 9 /l, which was successfully achieved in almost 80% of the patients, did not prevent two thirds of the bleeding. These findings indicate that thrombocytopenia was not the key risk factor for most bleeding episodes in this patient group. However, the conclusions of this work cannot be used as a recommendation for a change in platelet transfusion practice, as we have not tested the consequences of other prophylactic triggers.
Further examination is needed to clarify the significance of decreased platelet counts and the role of platelet transfusions in NBLD patients. Thrombocytopenia that was commonly evaluated with relation to bleeding should be carefully followed in NBLD patients, as it is associated with reduced survival. We recommend that any trial that lowers the prophylactic trigger should closely monitor the consequences in NBLD patients.
